All News

Budget cuts mean county health clinics will be unable to fill hundreds of jobs, leaving smaller staffs to serve low-income people in state that declined to expand Medicaid despite pleas from its hospitals and business leaders.

Emergency care providers vary in their understanding of a type of medical order intended to communicate seriously ill patients' choices for life-sustaining treatments, according to a pair of studies recently published.

The American Journal of Managed Care convened a discussion of 2 leading clinicians and 2 medical directors for leading payers, all of whom saw some merit in FDA's plans to bring oversight to the diagnostic testing market. The strongest advocate for greater FDA oversight was Daniel F. Hayes, MD, clinical director of the Breast Oncology Program at the University of Michigan, who will be a future president of the American Society of Clinical Oncology.

Ten oncology practices around the nation will initiate their accreditation process this year, which includes an on-site survey bu the Commission on Cancer.

A report released by the CDC, based on a survey conducted by the National Center for Health Statistics, found a significant decline since 2011.

NICE's first guideline on bladder cancer aims to improve the diagnosis and management of the seventh most common cancer in the UK.

The use of electronic alerts by hospitals treating patients with acute kidney injury may increase interventions without improving care, a study by Yale researchers found.

While California has made great strides to improve mental health prevention and early intervention, the state's Department of Managed Health Care found causes for concern regarding Kaiser Permanente's behavioral health services.

With the International Classification of Diseases, Tenth Revision, definitely being implemented on October 1, 2015, CMS just completed the first week of end-to-end testing of the new coding.

A lengthy report published by the Kaiser Family Foundation predicts widespread market disruption if ACA premium subsidies are lost under King vs. Burwell. Adverse selection, insurers exiting markets, and higher rates are just some of the possibilities.

Following the introduction of adaptive clinical trials, cancer researchers are now working on another revolutionary model, and they have the FDA's support in this effort. Named basket studies because they group different cancers together based on the driver mutation rather than the tumor of origin, these trials do not use the standard treatment as a control group, but look for a "Yes" or "No" response.

Significant results from an international phase 3 study, EDITION, resulted in the approval of Toujeo in treating patients with type 1 as well as type 2 diabetes.

Medical identity theft jumped 22% last year as more US health data becomes electronic and easier for cyber criminals to steal from doctors' offices, hospitals and insurers.

CMS has released proposed changes for the Medicare Advantage and Part D Prescription Drug Programs that help build a better, smarter healthcare system and move the Medicare program toward paying providers based on quality of care.

Project to research better way to treat neutropenia is 1 of 5 to get latest funding from Patient-Centered Outcomes Research Institute.

Eligible healthcare professionals participating in the Medicare Electronic Health Record (EHR) Incentive Program 2014 reporting year will have additional time to attest to meaningful use, according to an announcement from CMS.

H&R Block, the largest consumer tax preparer, said those who underestimated their 2014 income must repay an average of $530. Those who failed to get coverage at all must pay an average penalty of $172.

The study, published in the current issue of the Journal of the National Cancer Institute determined that the total cancer burden was highest among people in the 50-59 years age bracket, men who have sex with men, those living 5 or more years with AIDS, and non-Hispanic blacks. But the largest excess burden was among people 15-29 years old.

The governing body for public health in the UK, National Institute for Health and Care Excellence, has refused to fund Provenge citing a high-price for the benefit the tretament provides. This may not be the best news for Valeant Pharmaceuticals which recently bought the regimen from the bankrupt Dendreon Corp.

A study published in the journal Cancer provides insights that may help physicians understand patients' preferences regarding their care, which may be crucial for optimizing patient participation in treatment decisions.

For decades, hospital executives across the country have justified expensive renovation and expansion projects by saying they will lead to better patient reviews and recommendations.

The difference in uninsured rates in states that have embraced the Affordable Care Act and those that have not became even starker in 2014, according to new results from the Gallup-Healthways Well-Being Index.

The study, conducted in 2 separate patient cohorts at St. Jude Children's Hospital and the Children's Oncology Group and published in the The Journal of the American Medical Association, found that children with gene variants in the CEP72 gene were more sensitive to vincristine-induced peripheral neuropathy.

Interim analysis of a clinical trial evaluating adjuvant sorafenib, sunitinib or placebo in patients with advanced renal cell carcinoma found the recurrence rates and the disease-free survival were similar between all three treatment regimens.

The president of the UCLA Health System, which is still contending with the outbreak of a superbug that infected 7 patients and killed 2, is stepping down from his position for a new appointment as president and chief executive officer of Geisinger Health System.

A study published today in JAMA suggests that former long-term smokers who have quit for more than 15 years would benefit from access to the lung cancer screening recently approved for coverage by Medicare; however, these smokers no longer meet the criteria.

Study results showed participants receiving Farydak with bortezomib and dexamethasone saw a progression-free survival for about 10.6 months,compared to 5.8 months in participants treated with bortezomib and dexamethasone alone.

"The growth of ORIEN coincides with President Obama's announcement and the recognition that molecularly targeted medicine holds tremendous promise for all disease, particularly cancer," said Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute.

The deals, with Flexus and Rigel, will add another molecule to the company's immunotherapy pipeline and also provide access to a TGF-beta receptor inhibitor to be used in combination with Yervoy and Opdivo.

With the availability of government incentives, electronic health record use among hospital emergency departments and outpatient departments increased sharply from 2006 to 2011, according to a new analysis from the National Center on Health Statistics.